Have a feature idea you'd love to see implemented?
Let us know!
AVTE Aerovate Therapeutics Inc
Price (delayed)
$2.61
Market cap
$75.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.99
Enterprise value
$44.79M
Highlights
AVTE's debt is down by 33% YoY and by 21% from the previous quarter
The quick ratio has grown by 41% from the previous quarter but it has contracted by 6% YoY
The net income has declined by 21% year-on-year but it rose by 3.8% since the previous quarter
The company's equity fell by 36% YoY and by 15% QoQ
Key stats
What are the main financial stats of AVTE
Market
Valuations
Earnings
Shares outstanding
28.87M
Market cap
$75.36M
Enterprise value
$44.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$84.56M
EBITDA
-$84.25M
Free cash flow
-$75.01M
Per share
Balance sheet
Liquidity
EPS
-$2.99
Free cash flow per share
-$2.6
Book value per share
$2.79
Revenue per share
$0
TBVPS
$3.15
Total assets
$90.96M
Total liabilities
$10.47M
Debt
$540,000
Equity
$80.49M
Working capital
$80.29M
Debt to equity
0.01
Current ratio
8.78
Quick ratio
8.6
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-77.5%
Return on equity
-90.2%
Return on invested capital
-119%
Return on capital employed
-104.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVTE stock price
How has the Aerovate Therapeutics stock price performed over time
Intraday
-1.88%
1 week
1.95%
1 month
11.54%
1 year
-82%
YTD
-88.47%
QTD
24.88%
Financial performance
How have Aerovate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$90.26M
Net income
-$84.61M
Gross margin
N/A
Net margin
N/A
The net income has declined by 21% year-on-year but it rose by 3.8% since the previous quarter
AVTE's operating income is down by 20% year-on-year but it is up by 4.2% since the previous quarter
Growth
What is Aerovate Therapeutics's growth rate over time
Valuation
What is Aerovate Therapeutics stock price valuation
P/E
N/A
P/B
0.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
AVTE's EPS is down by 9% year-on-year but it is up by 4.8% since the previous quarter
The price to book (P/B) is 77% less than the last 4 quarters average of 4.0
The company's equity fell by 36% YoY and by 15% QoQ
Efficiency
How efficient is Aerovate Therapeutics business performance
The return on equity has dropped by 63% year-on-year and by 8% since the previous quarter
The company's return on invested capital has shrunk by 58% YoY and by 11% QoQ
The return on assets has dropped by 54% year-on-year and by 7% since the previous quarter
Dividends
What is AVTE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVTE.
Financial health
How did Aerovate Therapeutics financials performed over time
The quick ratio has grown by 41% from the previous quarter but it has contracted by 6% YoY
The total liabilities has declined by 39% since the previous quarter and by 31% year-on-year
AVTE's debt is 99% less than its equity
The company's equity fell by 36% YoY and by 15% QoQ
AVTE's debt is down by 33% YoY and by 21% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.